Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
Details
Publication Year 2023-06,Volume 64,Issue #6,Page 869-872
Journal Title
Journal of Nuclear Medicine
Publication Type
Research article
Abstract
The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first (177)Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.
Publisher
Society of Nuclear Medicine and Molecular Imaging
Keywords
Male; Humans; *Prostatic Neoplasms/radiotherapy/drug therapy; Radioisotopes/therapeutic use; Patient Reported Outcome Measures; genitourinary oncology; patient-reported outcomes; prostate cancer; radionuclide therapy; radiopharmaceuticals
Department(s)
Cancer Imaging
PubMed ID
36635088
Open Access at Publisher's Site
https://doi.org/10.2967/jnumed.122.264946
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-09-05 07:38:03
Last Modified: 2023-09-05 07:38:18

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙